Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Sulfasalazin (ausschl. FMR, N2), ATC M01CX02 f. d. Z. 01.11.26-31.10.28 (zzgl. V.-Option 1x12 Mon)

TENDER DESCRIPTION

DAK-Gesundheit assumes that, due to the lack of a selection decision and thus the non-discriminatory possibility of access for all pharmaceutical companies, this procedure does not fall within the scope of cartel tendering law. It ends automatically regardless of anything else upon entry into force of the exclusive contract for the active ingredient sulfasalazine (exclusively FMR in standard pack size N2), ATC M01CX02, as a result of a formal tender procedure in accordance with the rules of Part 4 of the GWB with one or more contracting parties. To ensure that the variety of potential contracting parties within the admission model is taken into account, each pharmaceutical company is allowed, at any time during the contract term, to enter into a framework agreement under the same conditions. The contractual documents required for this are available for download via the online portal www.dtvp.de/center under the link stated under 5.1.11. The conditions for concluding, or for later accession to, the contracts that first enter into force on 01.11.2026 are the complete and timely submission of the following documents (available for download via the link stated under 5.1.11) to the…

TENDER BRIEF

TENDER DOCUMENTS